Research Paper Volume 15, Issue 6 pp 2208—2220

Figure 1. GALNT2 expression was highly expressed in GBM and IDH1 wildtype GBM. (A, D, G) GALNT2 expression was increased in WHO IV glioma in TCGA (A), CGGA (D), and Rembrandt (G) data sets. (B, E, H) GALNT2 expression was markedly elevated in IDH-wildtype gliomas in TCGA (B) and CGGA (E) and Rembrandt (H) data sets. (C, F, I) Increased GALNT2 expression predicts a poor prognosis of glioma patients assessed by Kaplan-Meier curves in TCGA (C) and CGGA (F), and Rembrandt (I) data sets. (J) GALNT2 protein expression was convincingly increased in WHO IV glioma. Representative images of IHC staining of GALNT2 protein in different grades of glioma specimens were shown. Scale bar: 100 μm. (K) Correlation between GALNT2 protein expression and WHO grades of gliomas. Clinical glioma specimens from 46 glioma patients were IHC-stained with anti-GALNT2 primary antibody. (L) GALNT2 expression was elevated in IDH1 wildtype group glioma patients. *, ** and *** indicate p < 0.05, p < 0.01 and p < 0.001, respectively.